KPTI240517C1000
- 0.10
- 0.000.00%
Karyopharm Therapeutics Newsroom
Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 price target.
Karyopharm Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 684.31% HC Wainwright & Co. → $8 Reiterates Buy → Buy 03/01/2024 684.31% HC Wainwright & Co. $1
Optimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical Trials
Karyopharm Therapeutics (KPTI) Gets a Buy From Barclays
Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Express News | Karyopharm Therapeutics Inc : Leerink Partners Cuts Target Price to $2 From $3
Karyopharm Therapeutics | 10-Q: Quarterly report
Karyopharm Announces Significant Refinancing Transactions
Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review
Karyopharm Therapeutics Inc. Q1 Loss Increases, but Beats Estimates
Karyopharm Therapeutics Enhances Financial Stability and Liquidity
Express News | Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M
Express News | Karyopharm Announces Refinancing Transactions $148M Of Existing Convertible Notes Due In 2025 To Be Exchanged for $111M Of New Convertible Notes Due In 2029 And Warrants, Issues New $100M Senior Secured Term Loan Due in 2028a
Karyopharm Therapeutics Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $33.126M Miss $34.473M Estimate
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 6.67 percent decrease over losses o
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, Vs. Street Est of $34.5M
07:37 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M
Karyopharm Therapeutics Still Sees 2024 U.S. Xpovio Net Product Revenue $100M-$120M >KPTI
Karyopharm Therapeutics Still Sees 2024 U.S. Xpovio Net Product Revenue $100M-$120M >KPTI
Express News | Karyopharm Therapeutics- $148 Mln of Existing Convertible Notes Due in 2025 to Be Exchanged for $111 Mln of New Convertible Notes Due in 2029,Warrants
Karyopharm Therapeutics Backs 2024 View of Rev $140M-$160M >KPTI
Karyopharm Therapeutics Backs 2024 View of Rev $140M-$160M >KPTI
Express News | Karyopharm Therapeutics Inc - Expects That Existing Cash, Cash Equivalents and Investments Will Be Sufficient to Fund Planned Ops Into End of 2025